Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.
Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.
Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.
Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.
Prestige Consumer Healthcare Inc. (NYSE:PBH) is set to release its fiscal 2023 fourth quarter and year-end earnings on May 4, 2023, before market opening. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss these results. Investors can access the live webcast through the company's Investor Relations page or register for a phone call. A replay of the call will be available for a week post-event. Prestige Consumer Healthcare offers a diverse range of consumer healthcare products including Monistat®, BC®, Dramamine®, and many others, serving markets across the U.S., Canada, Australia, and beyond.
Prestige Consumer Healthcare (PBH) reported Q3 fiscal 2023 revenues of $275.5 million, a 0.4% increase from the previous year, with 1.8% growth excluding currency effects. Net income rose to $52.0 million, yielding diluted EPS of $1.04, up 5.1%. For the first nine months, revenues reached $841.9 million, a 2.7% increase year-over-year. The International OTC segment saw record revenues, growing 15.0% to $38.6 million. Management anticipates fiscal 2023 revenues between $1,120 and $1,122 million, projecting over 3% growth.